BONE BIOLOGICS CORPORATION: 10-Q filed 2022-05-13

Name: BONE BIOLOGICS CORPORATION: 10-Q filed 2022-05-13
Creator: BONE BIOLOGICS CORPORATION

What BONE BIOLOGICS CORPORATION reported in its quarterly report filed 2022-05-13 (fiscal Q1 2022): 20 published measures, 38 facts as tagged in accession 0001493152-22-013230.

This filing

Form: 10-Q (quarterly report)
Filed: 2022-05-13
Fiscal period: fiscal Q1 2022
Accession: 0001493152-22-013230 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BONE BIOLOGICS CORPORATION filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2022-03-31	6,093,714	USD
At 2021-12-31	6,675,365	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2022-03-31	54,913	USD
At 2021-12-31	99,909	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2022-03-31	6,038,801	USD
At 2021-12-31	6,575,456	USD
At 2021-03-31	-14,124,057	USD
At 2020-12-31	-13,692,310	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2022-03-31	5,814,586	USD
At 2021-12-31	6,675,365	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-689,499	USD	90
2021-01-01 to 2021-03-31	-431,747	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-860,779	USD	90
2021-01-01 to 2021-03-31	-127,983	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2021-01-01 to 2021-03-31	199,148	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2022-03-31	-71,165,106	USD
At 2021-12-31	-70,475,607	USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	10,350,579	shares	90
2021-01-01 to 2021-03-31	2,911,333	shares	90

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-0.07	USD/shares	90
2021-01-01 to 2021-03-31	-0.15	USD/shares	90

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	33,077	USD	90

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	152,844	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-656,422	USD	90
2021-01-01 to 2021-03-31	-180,924	USD	90

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	656,422	USD	90
2021-01-01 to 2021-03-31	180,924	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	36,400	USD	90
2021-01-01 to 2021-03-31	45,500	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2022-03-31	10,350,579	shares
At 2021-12-31	10,350,574	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2022-03-31	77,193,557	USD
At 2021-12-31	77,040,713	USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	-656,422	USD	90
2021-01-01 to 2021-03-31	-431,747	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	620,022	USD	90
2021-01-01 to 2021-03-31	135,424	USD	90

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

Period	Value	Unit	Days
2022-01-01 to 2022-03-31	33,077	USD	90

Inspect the source

Entity: BONE BIOLOGICS CORPORATION / CIK 0001419554
Captured: 2026-09-20T08:02:52.100Z
SEC response SHA-256: 7c2684db7febb4ea6b03577e138dc91ed20e12534f1d96c178894d4b68a7b815

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001419554.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))